Results 191 to 200 of about 22,239 (295)

Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study. [PDF]

BMJ Open
Hong SH, Lee H, Lee SY, Sung YA, Hong YS, Song DK, Jung H, Kim MH.   +7 more
europepmc   +1 more source

Correlation Analysis of 24‐h Minimum Heart Rate Levels and Deceleration Capacity of Heart Rate in Patients With Type 2 Diabetes Mellitus Complicated With Essential Hypertension

Annals of Noninvasive Electrocardiology, Volume 31, Issue 3, May 2026.
Sex‐specific 24‐hour minimum heart rate (MHR) stratification in patients with type 2 diabetes mellitus and essential hypertension (T2DM‐EH). Three key findings are shown from subgroup analysis: (1) In the normal MHR group (Group B), advancing age independently predicts reduced deceleration capacity (DC) in both sexes.
Pingping Wu, Zhengrong Xu, Xiuyu Zheng, Linying Gong, Hongkun Qiao, Guoyan Xu, Qunfang Xie   +6 more
wiley   +1 more source

Effect of antidiabetic medication adherence on risk of all-cause mortality and cardiovascular diseases in type 2 diabetes patients: Impact of antidiabetic adherence on cardiovascular disease. [PDF]

Medicine (Baltimore)
Seo DH, Ha KH, Kim SH, Kim DJ.
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura. [PDF]

Front Immunol
Kawamoto H, Sasaki N, Ueda Y, Ishii N, Sawada Y.   +4 more
europepmc   +1 more source

Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their ...
Mohamed Hassanein, Li Xi, Rathi D. Ryan, Zhan (Harold) Ye, Nessy Tania, Yamato Sano, Joshua Varghese, Diogo Branquinho, Anna Sapone   +8 more
wiley   +1 more source

Repurposing dipeptidyl peptidase-4 inhibitor for Parkinson's disease prevention: A drug-target Mendelian randomization study. [PDF]

Neurotherapeutics
Lee JY, Park DG, Sung J.
europepmc   +1 more source

Diabetes management in people undergoing metabolic‐bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) Group

Diabetic Medicine, Volume 43, Issue 5, May 2026.
Abstract The global prevalence of obesity and diabetes continues to rise, with metabolic‐bariatric surgery recognised as an effective intervention for obesity and type 2 diabetes, offering potential for type 2 diabetes remission and improved glycaemic control. This guideline, developed by the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP)
Jeffrey W. Stephens, Ketan Dhatariya, Andrew J. Beamish, Dimitri J. Pournaras, Alexander D. Miras, Nader Raafat, Georgia Noble‐Bell, Rachel Cadwallader Buckland, Omar G. Mustafa   +8 more
wiley   +1 more source

Real‐world treatment trajectories preceding GLP‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3692-3702, May 2026.
Abstract Aims To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
Franziska S. Ulrich, Morten Frost Nielsen, Nicola Napoli, Andrea M. Burden   +3 more
wiley   +1 more source

Dipeptidyl peptidase-4 inhibitors are associated with a lower risk of osteoarthritis in patients with type 2 diabetes. [PDF]

Ther Adv Musculoskelet Dis
Chen YH, Byers Kraus V, Chang YS, Lin TM, Lee HY, Chang CK, Kuo TT, Chen JH, Chang CC.   +8 more
europepmc   +1 more source